Our work 

We combine science, technology, and creativity to develop advanced medical devices, engineered tissues, and in vitro systems that support regenerative medicine and therapeutic development. 

Hemorrhage control 

Hemostatic device: An innovative topical product with hemostatic, antimicrobial, and regenerative properties, currently under development.

Uncontrolled bleeding remains one of the leading causes of preventable death in trauma and surgical settings. Rapid and effective bleeding control is essential to reduce complications, improve patient outcomes, and save lives.
Hemostatic agents play a crucial role in achieving this goal by promoting faster clot formation, stabilizing the wound, and reducing the need for more invasive interventions. Their use is especially critical in emergency care, military medicine, and surgeries where traditional methods such as pressure or sutures may not be sufficient or practical.
As the demand for safer, faster, and more effective bleeding control solutions grows, the development of next-generation hemostatic products becomes increasingly important.

Bioprinting

3D-Bioprinted Cardiac Model: Development of functional 3D-bioprinted cardiac microtissues for research, toxicity testing, and future therapeutic applications.

Cardiovascular diseases are the leading cause of death worldwide, often resulting in irreversible damage to heart tissue. Since the heart has a limited ability to regenerate, patients affected by conditions such as myocardial infarction are left with long-term complications and reduced quality of life.

Bioprinting cardiac tissue offers a promising solution by enabling the creation of functional, patient-specific heart tissue in the lab. This technology has the potential to support drug testing, disease modelling, and eventually tissue replacement therapies addressing a critical gap where conventional treatments fall short.
Advancing cardiac bioprinting is a key step toward more effective, personalized, and regenerative solutions in cardiovascular medicine.